Evidence map›Paper›PMID 38127078›Full record

ArticleeLife2023

Identifying metabolic features of colorectal cancer liability using Mendelian randomization.

Caroline Bull, Emma Hazelwood, Joshua A Bell, Vanessa Tan, Andrei-Emil Constantinescu, Carolina Borges, Danny Legge, Kimberley Burrows, Jeroen R Huyghe, Hermann Brenner and 12 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 7 countries.

Caroline Bull *MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-2176-5120
Emma Hazelwood *MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-4888-6037
Joshua A BellMRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Vanessa TanMRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.ORCID 0000-0001-7938-127X
Andrei-Emil ConstantinescuMRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Carolina BorgesMRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Danny LeggeTranslational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-3897-5861
Kimberley BurrowsMRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Jeroen R HuyghePublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, United States.ORCID 0000-0001-6027-9806
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sergi Castellvi-BelGastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.
Andrew T ChanDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, United States.
Sun-Seog KweonDepartment of Preventive Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.
Loic Le MarchandUniversity of Hawaii Cancer Center, Honolulu, United States.
Li LiDepartment of Family Medicine, University of Virginia, Charlottesville, United States.
Iona ChengDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, United States.
Rish K PaiDepartment of Pathology and Laboratory Medicine, Mayo Clinic, Scottsdale, United States.
Jane C FigueiredoDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, United States.
Neil MurphyNutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.
Marc J GunterNutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.
Nicholas J TimpsonMRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Emma E VincentMRC Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-8917-7384
University of Bristol · GBCentre international de recherche sur le cancer · FRBroad Institute · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZACedars-Sinai Medical Center · USCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESChonnam National University Hospital · KRGerman Cancer Research Center · DEMayo Clinic in Arizona · USUniversity of California, San Francisco · USUniversity of Hawaiʻi at Mānoa · USUniversity of Virginia · US

Funding

Cancer Research UK C18281/A19169Cancer Research UK C18281/A29019Cancer Research UK C18281/A30905Diabetes UK 17/0005587Medical Research Council 102215/2/13/2Medical Research Council MC_UU_00011/1Medical Research Council MC_UU_00011/4Medical Research Council MC_UU_00011/6Medical Research Council MC_UU_12013/1Medical Research Council MR/N0137941/1Medical Research Council MR/P014054/1Wellcome TrustWellcome Trust 102215/2/13/2Wellcome Trust 10.35802/202802Wellcome Trust 10.35802/204813Wellcome Trust 202802/Z/16/ZWellcome Trust 204813/Z/16/ZWorld Health Organization 001
6 · The paper itself

Abstract

Background: Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival. Methods: To investigate whether changes in circulating metabolites characterize the early stages of colorectal cancer (CRC) development, we examined the associations between a genetic risk score (GRS) associated with CRC liability (72 single-nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N = 6221). Linear regression models were applied to examine the associations between genetic liability to CRC and circulating metabolites measured in the same individuals at age 8 y, 16 y, 18 y, and 25 y. Results: The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P < 0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N = 118,466, median age 58 y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk. Conclusions: These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism and suggest that fatty acids may play an important role in CRC development. Funding: This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/.

Indexed as

Colorectal NeoplasmsGenetic Risk ScoreMendelian Randomization AnalysisAdolescentAdultChildFatty AcidsHumansLongitudinal StudiesMiddle AgedFatty Acidscancer biologycolorectal cancerepidemiologyglobal healthhumanMendelian randomizationmetabolomicsobesity

Identifiers

PMID38127078
PMCPMC10735227
OpenAlexW4385260388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.